Parnell Launches First Generic Resflor Gold®, Shaking Up Cattle Health Market

OVERLAND PARK, Kan. – April 01, 2026 – In a move poised to reshape the economic landscape of cattle production, Parnell Technologies Pty. Ltd. has announced the U.S. launch of nixiFLOR®, the first FDA-approved generic version of the widely used drug Resflor Gold®. The injectable solution is approved for treating Bovine Respiratory Disease (BRD) and controlling its associated fever in beef and non-lactating dairy cattle, offering a significant new option for producers grappling with one of the industry's most persistent and costly challenges.

This launch introduces direct competition into a key segment of the veterinary pharmaceutical market, promising a cost-effective alternative for a condition that costs the North American cattle industry billions annually.

The Pervasive Cost of Bovine Respiratory Disease

Bovine Respiratory Disease is not merely a single illness but a complex syndrome of respiratory infections that stands as the most significant health and economic challenge facing the beef and dairy industries. Industry data indicates that BRD is responsible for an overwhelming majority of morbidity and mortality in feedlots, accounting for up to 80% of sickness and 75% of deaths. The economic toll is staggering, with the global market for BRD treatments valued at over USD 1.2 billion in 2024 and projected to grow substantially.

For individual producers, the costs extend far beyond the price of medication. They include decreased weight gain, reduced feed efficiency, increased labor for managing sick animals, and the ultimate loss from animal death. This multifaceted financial drain makes the cost of treatment a critical factor in the profitability of any cattle operation. The introduction of a more affordable, yet equally effective, therapeutic option could therefore have a profound impact on a producer's bottom line.

A Dual-Action, Bioequivalent Solution

Parnell's nixiFLOR contains the same active ingredients as its brand-name predecessor: florfenicol, a potent broad-spectrum antimicrobial, and flunixin meglumine, a non-steroidal anti-inflammatory drug (NSAID). This combination provides a powerful two-pronged attack, targeting the bacterial pathogens that cause BRD while simultaneously reducing the fever and inflammation that hinder an animal's recovery.

“At Parnell, we are committed to bringing high-quality, proven products to market with the reliability and pricing veterinarians and producers need,” said Pablo Lamberto, President of U.S. Operations, in a statement accompanying the launch. “nixiFLOR® delivers exactly that, competitive pricing and bioequivalent performance that cattle operations can depend on.”

The U.S. Food and Drug Administration's approval hinges on its determination that nixiFLOR is bioequivalent to Resflor Gold®. This designation is critical, as it certifies that the generic drug is absorbed and acts within the animal's body in the same manner and to the same extent as the original. The FDA's Center for Veterinary Medicine (CVM) employs rigorous standards, ensuring that a bioequivalent drug is identical in strength, dosage form, and route of administration, and will deliver the same therapeutic effect and safety profile. This allows veterinarians and producers to adopt the generic with confidence in its performance.

Furthermore, the single-dose subcutaneous administration simplifies treatment protocols. Reducing the number of times an animal must be handled and run through a chute not only decreases stress on the animal but also saves valuable labor and time, enhancing overall operational efficiency.

Reshaping the Competitive Landscape

The launch of nixiFLOR is a significant strategic maneuver in the highly competitive animal health market, which is dominated by giants like Zoetis, Elanco, and Merck Animal Health—the manufacturer of Resflor Gold®. For years, Resflor Gold® has been an industry standard, holding a unique position as a single-dose combination therapy for BRD. The arrival of the first generic equivalent signals a potential market disruption.

Historically, the introduction of generic drugs in both human and animal health leads to increased price competition, often forcing brand-name manufacturers to adjust their pricing strategies. This dynamic benefits the end-user by making essential treatments more accessible and affordable. For Parnell, a global veterinary pharmaceutical company, the launch represents a targeted effort to capture market share by addressing a clear need for cost-effective solutions.

“BRD remains one of the most significant challenges in cattle production,” noted Justin Miller, VP of U.S. Commercial Operations for Parnell. “nixiFLOR® provides a trusted dual-action solution that helps protect herd health while supporting producer profitability.”

As with all florfenicol-containing products, nixiFLOR® is available by prescription only and must be used under the guidance of a licensed veterinarian. This requirement underscores the importance of professional diagnosis and oversight in managing BRD and combating the broader threat of antimicrobial resistance. The availability of a lower-cost option may empower veterinarians to prescribe a full, effective course of treatment without producers being tempted to cut corners due to cost, ultimately supporting better stewardship of these vital medicines and improving animal welfare outcomes across the board.